Methods of treating eye diseases in diabetic patients
View Patent ↗The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
1. A method of treating a diabetic patient suffering from an eye disease which comprises administering to the patient intravitreally a composition comprising a double-stranded compound having the structure:
wherein each of A, C, G and U represents a ribonucleotide; wherein in alternating ribonucleotides in each of the antisense strand and the sense strand, a 2′-O-methyl group is present in the sugar residue;
wherein the ribonucleotide at each of the 5′ terminus and the 3′ terminus of the antisense strand comprises a 2′-O-methyl group in the sugar residue;
wherein the ribonucleotide at each of the 5′ terminus and the 3′ terminus of the sense strand is unmodified in the sugar residue;
wherein each ribonucleotide at the 5′ terminus and the 3′ terminus of the antisense strand and of the sense strand is independently phosphorylated or non-phosphorylated; and
wherein each vertical line (|) represents base pairing; and
a pharmaceutically acceptable carrier or excipient;
wherein the composition is administered in an amount effective to treat the patient.
2. A method according to claim 1 , wherein the eye disease is diabetic macular edema (DME).
3. A method according to claim 1 , wherein the eye disease is diabetic retinopathy.
4. The method of claim 1 , wherein the ribonucleotide at the 3′ terminus of both the antisense strand and the sense strand is non-phosphorylated.
5. The method of claim 1 , wherein in the antisense strand and in the sense strand, the ribonucleotide at the 5′ terminus and at the 3′ terminus is non-phosphorylated.
6. The method of claim 1 , wherein the composition is administered intravitreally by injection.
7. A method of treating a patient suffering from diabetic macular edema (DME) which comprises administering to the patient intravitreally a composition comprising a compound having the structure:
wherein each of A, C, G and U represents a ribonucleotide;
wherein in alternating ribonucleotides in each of the antisense strand and the sense strand, a 2′-O-methyl group is present in the sugar residue;
wherein the ribonucleotide at each of the 5′ terminus and the 3′ terminus of the antisense strand comprises a 2′-O-methyl group in the sugar residue;
wherein the ribonucleotide at each of the 5′ terminus and the 3′ terminus of the sense strand is unmodified in the sugar residue;
wherein each vertical line (|) represents base pairing; and
a pharmaceutically acceptable carrier or excipient;
wherein the composition is administered in an amount effective to treat the patient.
8. The method of claim 6 , wherein the ribonucleotide at the 3′ terminus of both the antisense strand and the sense strand is non-phosphorylated.
9. The method of claim 6 , wherein in the antisense strand and in the sense strand, the ribonucleotide at the 5′ terminus and at the 3′ terminus is non-phosphorylated.
10. The method of claim 7 , wherein the composition is administered intravitreally by injection.